Everyday Health on MSN
Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound
Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...
Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...
Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.
A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.
There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.
Lilly stock was up 4.8% at $969.14, putting it on pace for a record closing high, according to Dow Jones Market Data. The ...
Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.
The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...
Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...
Eli Lilly is currently redefining its market position through a series of strategic developments. The pharmaceutical giant finds itself at a pivotal moment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results